10 results were returned
The Australian Pharmaceutical Benefits Scheme (PBS) provides for and regulates government subsidies for the supply of certain medicines. A requirement to receive subsidised medicine under the PBS is that the medicine ...
Currently, medicinal cannabis in Australia is regulated by a series of overlapping pieces of State and Federal legislation: regulatory regimes targeting narcotic drugs, poisons and controlled substances and therapeutic ...
Full Federal Court of Australia finds that common descriptive elements can be central to a comparative analysis of trade marks.
On 16 August 2018, the Intellectual Property Laws Amendment (Productivity Commission Response Part 1 and Other Measures) Bill 2018 (Bill) passed through both Houses of Parliament and will shortly come into force upon ...
The Australian Government has committed $206.4 million to a patent box tax incentive scheme to encourage investment in medical and biotechnology innovation.
In response to the COVID-19 pandemic, the Australian Federal Minister for Health has exercised his power under section 41GS of the Therapeutic Goods Act 1989 (Cth) (the Act) to exempt certain medical devices from the ...
Late last week, the Full Federal Court of Australia confirmed that the mere act of filing a Pharmaceutical Benefits Scheme (PBS) application for a generic pharmaceutical product is not, of itself, an act of infringement ...
In Australia the application of the Patent Term Extension provisions of the Patents Act 1990 have been construed narrowly so that PTEs are applicable to only certain types of pharmaceutical patents.
Our Australian competition and IP team have recently contributed a chapter to the Fifth Edition of The Intellectual Property and Antitrust Review.
Australia's first biosimilar interlocutory injunction.